April 1, 2017
Xcenda Expertise and Thought Leadership Showcased at ISPOR 22nd Annual International Meeting in Boston
Xcenda Continues Excellence in Innovative Research
Join Xcenda's Global HEOR consultants in Boston as they demonstrate their global perspective, as well as findings from the latest evidence-based research at ISPOR's 22nd Annual International Meeting from May 20-24, 2017. Meet us at booth #817.
Please join us for the following scientific presenations.
FDAMA 114 and the 21st Century Cures Act: Insights from Payers and Manufacturers, and Implications for the Exchange of Health Care Economic Information
Tuesday, May 23, 2017 | 12:30 PM - 1:30 PM ET | Sheraton-Grand Ballroom
The 21st Century Cures Act was signed into law on December 13, 2016. The stated aim of the legislation is to modernize and personalize healthcare, encourage innovation, support research, and streamline the US healthcare system to promote the delivery of better and faster “cures” to more patients. The Act has four major sections, or titles. The first three —“Discovery,” “Development,” and “Delivery”— track the sequence of how medical innovations reach patients. The fourth title, “Medicaid, Medicare, and Other Reforms,” itemizes the activities to pay for the cost of the legislation. Title II, “Development”, includes a provision on pharmaceutical manufacturers’ promotion of health care economic information (HCEI). The Act makes changes to Section 114 of the Food and Drug Modernization Act of 1997 (FDAMA 114), providing clarity and flexibility for manufacturers to communicate HCEI to “a payer, formulary committee or other similar entity” responsible for “the selection of drugs for coverage or reimbursement”. This symposium will provide a brief overview of the 21st Century Cures Act, with a focus on the provision to facilitate dissemination of HCEI. Insights from US payers and pharmaceutical manufacturers on the implications of the 21st Century Cures Act on the exchange of HCEI will be shared and discussed in further detail during this symposium.
•Moderator: Jay Jackson, PharmD, MPH
Senior Vice President, Scientific Consulting, Xcenda, LLC, Palm Harbor, FL, USA
•Speaker: Eleanor M. Perfetto, PhD, MS
Senior Vice President, Strategic Initiatives, National Health Council, Professor, Pharmaceutical Health Services Research, University of Maryland School of Pharmacy, National Health Council, Washington, DC, USA
•Speaker: Jan Hansen, PhD
Vice President, Evidence for Access (E4A) Medical Unit, US Medical Affairs, Genentech, South San Francisco, CA, USA
•Speaker: Laurent Carter, MBA
Vice President, Head of Strategic Payer Marketing, Bristol-Myers Squibb, Plainsboro, NJ, USA
Every Brand has Challenges. We have Answers. Talk to Us.
We're problem solvers. Through one point of contact, we'll connect your team with the collective insights and experience of our payer marketers, health economists, policy analysts, reimbursement strategists, training specialists, and -- most importantly -- experts who understand your world and what success demands.
Talk to us about your goals. We won't bore you with a sales pitch for our services. But you will get insights and innovative strategies you hadn't thought of before.
Contact us to schedule a meeting in our client room at the Boston Marriott Copley Place.